SWM
VIR icon

Spire Wealth Management’s Vir Biotechnology VIR Stock Holding History

Spire Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-602
Closed -$15K – 2604
2022
Q4 		$15K Buy
+602
New +$14.8K ﹤0.01% 1485

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Spire Wealth Management's VIR Position: Q1 2023 in Review

Spire Wealth Management sold out of Vir Biotechnology (VIR) in Q1 2023, closing a stake of 602 shares — an estimated $15K sold.

Spire Wealth Management first reported a position in VIR in Q4 2022 and held it in 1 quarter. The position peaked at $15K in Q4 2022. 232 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

  • Spire Wealth Management reported no remaining Vir Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Spire Wealth Management sold 602 Vir Biotechnology shares in Q1 2023, an estimated $15K.
  • Spire Wealth Management first reported a position in Vir Biotechnology in Q4 2022 and held it in 1 quarter.
  • Spire Wealth Management's Vir Biotechnology position peaked at $15K in Q4 2022.
  • 232 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Spire Wealth Management's 13F filing for Q1 2023, filed 9 May 2023.